ArticleJournal of natural products2021
Leveraging Peptaibol Biosynthetic Promiscuity for Next-Generation Antiplasmodial Therapeutics.
Article in Journal of natural products, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Draft genome sequence of the peptaibol producerMicrobiology resource announcements · 2026Article
- NMR Analysis and Assignment of a Biosynthesis Gene Cluster for Trichokonins VI and VIII, Antiplasmodial Large Peptaibols Produced by aACS omega · 2025Article
- Cytotoxic Peptidic Metabolites Isolated from the Soil-Derived FungusMolecules (Basel, Switzerland) · 2025Article
- Coniontins, lipopetaibiotics active against Candida auris identified from a microbial natural product fractionation library.Nature communications · 2025Article
- Genome-Guided Metabolomic Profiling of Peptaibol-ProducingInternational journal of molecular sciences · 2025Article
- Fungal-derived methyldeoxaphomins targetProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Understanding the Antiplasmodial Action of Resistance-Refractory Xanthoquinodin A1.ACS infectious diseases · 2024Article
- Identification of fungal natural products with potent inhibition inMicrobiology spectrum · 2024Article
- Antiplasmodial peptaibols act through membrane directed mechanisms.Cell chemical biology · 2024Article
- Appraisal of Fungus-Derived Xanthoquinodins as Broad-Spectrum Anti-Infectives Targeting Phylogenetically Diverse Human Pathogens.Journal of natural products · 2023Article
- Identification of Fungus-Derived Natural Products as New Antigiardial Scaffolds.Microbiology spectrum · 2023Article
- Characterization of Peptaibols Produced by a Marine Strain of the FungusMetabolites · 2023Article
- Halovirs I-K, antibacterial and cytotoxic lipopeptaibols from the plant pathogenic fungus Paramyrothecium roridum NRRL 2183.The Journal of antibiotics · 2022Article
- Exploring Peptaibol's Profile, Antifungal, and Antitumor Activity of Emericellipsin A ofMolecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Malaria remains a worldwide threat, afflicting over 200 million people each year. The emergence of drug resistance against existing therapeutics threatens to destabilize global efforts aimed at controlling
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.